Evaluation and Management of the Febrile Child in the Conjugated Vaccine Era

Advances in Pediatrics

Volumn 53, Issue 1, 2006, Pages 255-278

  Akintemi, Olakunle B ^a,b   Roberts, Kenneth B ^a,b  

^a MOSES CONE HEALTH SYSTEM   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTRIAXONE; HAEMOPHILUS VACCINE; PNEUMOCOCCUS VACCINE; VACCINE;

BACTEREMIA; BACTERIAL INFECTION; FEVER; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; MICROBIOLOGY; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRESCHOOL CHILD; REVIEW; RISK FACTOR; STREPTOCOCCUS INFECTION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTRIAXONE; CHILD, PRESCHOOL; FEVER; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; URINARY TRACT INFECTIONS; VACCINES, CONJUGATE;

EID: 33748970719     PISSN: 00653101     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yapd.2006.04.015     Document Type: Review

References (131)

1. Finkelstein J.A., Christiansen C.L., and Platt R. Fever in pediatric primary care: occurrence, management, and outcomes. Pediatrics 105 (2000) 260-266
2. Schmitt B.D. Fever phobia: misconceptions of parents about fevers. Am J Dis Child 134 (1980) 176-181
3. May A., and Bauchner H. Fever phobia: the pediatrician's contribution. Pediatrics 90 (1992) 851-854
4. Kramer M.S., Naimark L., and Leduc D.G. Parental fever phobia and its correlates. Pediatrics 75 (1985) 1110-1113
5. Crocetti M., Moghbeli N., and Serwint J. Fever phobia revisited: have parental misconceptions about fever changed in 20 years?. Pediatrics 107 (2001) 1241-1246
6. Lee G.M., and Fleisher G.R. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med 152 (1998) 624-628
7. Baraff L.J., Bass J.W., Fleisher G.R., et al. Practice guidelines for management of infants and children 0-36 months of age with fever without source. Pediatrics 92 (1993) 1-12
8. Swindell S.L., Chetham M.M., and Roberts K.B. Fever without localizing signs: the problem of occult bacteremia. Semin Pediatr Infect Dis 4 (1993) 24-29
9. Belsey M.A. Pneumococcal bacteremia. A report of three cases. Am J Dis Child 113 (1967) 558-589
10. Heldrich F.J. Diplococcus pneumoniae bacteremia. Am J Dis Child 119 (1970) 12-17
11. Torphy D.E., and Ray C.G. Occult pneumococcal bacteremia. Am J Dis Child 119 (1970) 336-338
12. Burke J.P., Klein J.O., Gezon H.M., et al. Pneumococcal bacteremia. Review of 111 cases, 1957-1969, with special reference to cases with undetermined focus. Am J Dis Child 121 (1971) 353-359
13. Baron M.A., and Fink H.D. Bacteremia in private practice. Pediatrics 66 (1980) 171-175
14. Baron M.A., Fink H.D., and Cicchetti D.V. Blood cultures in private practice: an eleven year experience. Pediatr Infect Dis J 8 (1989) 2-7
15. Teele D.W., Pelton S.I., Grant M.J., et al. Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive children seen in a "walk-in" clinic. J Pediatr 87 (1975) 227-230
16. Teele D.W., Marshall R., and Klein J.O. Unsuspected bacteremia in young children: a common and important problem. Pediatr Clin North Am 26 (1979) 773-784
17. Dershewitz R.A., Wigder H.N., Wigder C.M., et al. A comparative study of the prevalence, outcome, and prediction of bacteremia in children. J Pediatr 103 (1983) 352-358
18. McLellan D., and Giebink G.S. Perspectives on occult bacteremia in children. J Pediatr 109 (1986) 1-8
19. McGowan J.E., Bratton L., Klein J.O., et al. Bacteremia in febrile children seen in a "walk-in" pediatric clinic. N Engl J Med 288 (1973) 1309-1312
20. Jaffe D.M., Tanz R.R., Davis A.T., et al. Antibiotic administration to treat possible occult bacteremia in febrile children. N Engl J Med 317 (1987) 1175-1180
21. Hamrick H.J., and Murphy T.F. Bacteremia in 28 ambulatory children. Clin Pediatr (Phila) 17 (1978) 109-112
22. Bass J.W., Steele R.W., Wittler R.R., et al. Antimicrobial treatment of occult bacteremia: a multicenter cooperative study. Pediatr Infect Dis J 12 (1993) 466-473
23. Fleisher G.R., Rosenberg N., Vinci R., et al. Intra-muscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr 124 (1994) 504-512
24. McCarthy P.L., Grundy G.W., Spiesel S.Z., et al. Bacteremia in children: an outpatient clinical review. Pediatrics 57 (1976) 861-868
25. Crocker P.J., Quick G., and McCombs W. Occult bacteremia in the emergency department. Diagnostic criteria for the young febrile child. Ann Emerg Med 14 (1985) 1172-1177
26. Waskerwitz S., and Berkelhamer J.E. Outpatient bacteremia: clinical findings in children under two years with initial temperature of 39.5°C or higher. J Pediatr 99 (1981) 231-233
27. Kuppermann N. Occult bacteremia in young febrile children. Pediatr Clin North Am 46 (1999) 1073-1109
28. Kuppermann N., Fleisher G.R., and Jaffe D.M. Predictors of occult pneumococcal bacteremia in young children. Ann Emerg Med 31 (1998) 679-687
29. McCarthy P.L., Sharpe M.R., Spiesel S.Z., et al. Observation scales to identify serious illness in febrile children. Pediatrics 70 (1982) 802-809
30. Teach S.J., and Fleisher G.R. Efficacy of an observation scale in detecting bacteremia in febrile children three to thirty-six months of age, treated as outpatients. Occult Bacteremia Study Group. J Pediatr 126 (1995) 877-881
31. Bennish M., Beern M.O., and Ormiste V. C-reactive protein and zeta sedimentation rate ratio as indicators of bacteremia in pediatric patients. J Pediatr 104 (1984) 729-732
32. Adams R.C., Dixon J.H., and Eichner E.R. Clinical usefulness of polymorphonuclear leukocyte vacuolization in predicting septicemia in febrile children. Pediatrics 62 (1978) 67-70
33. Liu C.H., Lehan C., Speer M.E., et al. Early detection of bacteremia in outpatient clinic. Pediatrics 75 (1985) 827-831
34. McCarthy P.L., Jekel J.F., and Dolan Jr. T.F. Comparison of acute phase reactants in pediatric patients with fever. Pediatrics 62 (1978) 716-720
35. Jaffe D.M., and Fleisher G.R. Temperature and total white blood cell count as indicators of bacteremia. Pediatrics 87 (1991) 670-674
36. Strait R.T., Kelly K.J., and Kurup V.P. Tumor necrosis factor-a, interleukin-1b, and interleukin-6 levels in febrile, young children with and without occult bacteremia. Pediatrics 104 (1999) 1321-1326
37. Isaacman D.J., Shults J., Gross T.K., et al. Predictors of bacteremia in febrile children 3 to 36 months of age. Pediatrics 106 (2000) 977-982
38. Isaacman D.J., and Burke B.L. Utility of the serum C-reactive protein for detection of occult bacteremia infection in children. Arch Pediatr Adolesc Med 156 (2003) 905-909
39. Pulliam P.N., Attia M.W., and Cronan K.M. C-Reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics 108 (2001) 1275-1279
40. Galetto-Lacour A., Zamora S.A., and Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 112 (2003) 1054-1060
41. Rothrock S.G., Harper M.B., Green S.M., et al. Do oral antibiotics prevent meningitis and serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia? A meta-analysis. Pediatrics 99 (1997) 438-444
42. Baraff L.J., Oslund S., and Prather M. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteremia. Pediatrics 92 (1993) 140-143
43. Shapiro E.D., Aaron N.H., Wald E.R., et al. Risk factors for development of bacterial meningitis among children with occult bacteremia. J Pediatr 109 (1986) 15-19
44. Bratton L., Teele D.W., and Klein J.O. Outcome of unsuspected pneumococcemia in children not initially admitted to the hospital. J Pediatr 90 (1977) 703-706
45. Marshall R., Teele D.W., and Klein J.O. Unsuspected bacteremia due to Haemophilus influenzae: outcome in children not initially admitted to hospital. J Pediatr 95 (1979) 690-695
46. Carroll W.L., Farrell M.K., Singer J.I., et al. Treatment of occult bacteremia: a prospective randomized clinical trial. Pediatrics 72 (1983) 608-612
47. Downs S.M., McNutt R.A., and Margolis P.A. Management of infants at risk for occult bacteremia: a decision analysis. J Pediatr 118 (1991) 11-20
48. Lieu T.A., Schwartz J.S., Jaffe D.M., et al. Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness. J Pediatr 118 (1991) 21-29
49. Harper M.B., Bachur R., and Fleisher G.R. Effect of antibiotic therapy in the outcome of outpatients with unsuspected bacteremia. Pediatr Infect Dis J 14 (1995) 760-767
50. Wald E.R., and Dashefsky B. Cautionary note on the use of empiric ceftriaxone for suspected bacteremia. Am J Dis Child 145 (1991) 1359-1361
51. Long S.S. Antibiotic therapy in febrile children: "best-laid schemes". J Pediatr 124 (1994) 585-588
52. American College of Emergency Physicians. Clinical policy for the initial approach to children under the age of 2 years presenting with fever. Ann Emerg Med 22 (1993) 628-637
53. Wears R.L., Stenklyt P.H., and Lutan R.C. Using decision tables to verify the logical consistency and completeness of clinical practice guidelines: fever without source under three. Acad Emerg Med 1 (1994) A35
54. In: Field M.J., and Lohr K.N. (Eds). Clinical practice guidelines: directions for a new program (1990), National Academy Press, Washington (DC)
55. Young P.C. The management of febrile infants by primary care pediatricians in Utah: comparison with published practice guidelines. Pediatrics 95 (1995) 623-627
56. Wittler R.R., Cain K.K., and Bass J.W. A survey about management of febrile children without source by primary care physicians. Pediatr Infect Dis J 17 (1998) 271-279
57. Baraff L.J. Management of fever without source in infants and children. Ann Emerg Med 36 (2000) 602-614
58. Alpern E.R., Alessandrini E.A., Bell L.M., et al. Occult bacteremia from a pediatric emergency department: Current prevalence, time to detection, and outcome. Pediatrics 106 (2000) 505-511
59. Yamamoto L.G., Worthyley R.G., Melish M.E., et al. A revised decision analysis of strategies in the management of febrile children at risk for occult bacteremia. Am J Emerg Med 16 (1998) 193-207
60. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49 RR-9 (2000) 1-35
61. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs). Emerging Infections Program Network. Streptococcus pneumoniae. U.S. Available at:http://www.cdc.gov/ncidod/dbmd/abcs. Accessed May 26, 2006.
62. Levine O.S., Farley M., Harrison L.H., et al. Risk factors for invasive pneumococcal disease: a population-based case-control study in North America. Pediatrics 103 (1999) E28. http://pediatrics.aappublications.org/cgi/content/full/103/3/e28 Accessed May 26, 2006
63. Eskola J., Black S., and Shinefield H. Pneumococcal conjugate vaccine. In: Plotkin S., and Orenstein W.A. (Eds). Vaccines (2004), Elsevier, Philadelphia 589-624
64. Bernatoniene J., and Finn A. Advances in pneumococcal vaccines: advantages for children and infants. Drugs 65 (2005) 229-255
65. O'Brien K.L., and Santosham M. Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases. Am J Epidemiol 159 (2004) 634-644
66. Shinefield H.R., Black S., Ray P., et al. Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18 (1999) 757-763
67. Rennels M.B., Edwards K.M., Keyserling H.L., et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197 in United States infants. Pediatrics 101 (1998) 604-611
68. Dagan R., Givon-Lavi N., Zamir O., et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185 (2002) 927-936
69. Obaro S.K., Adegbola R.A., Banya W.A., et al. Carriage of pneumococci after pneumococcal vaccination. Lancet 348 (1996) 271-272
70. Mbelle N., Huebner R.E., Wasas A.D., et al. Immunogenicity and impact on nasopharyngeal carriage of a nonvalent pneumococcal conjugate vaccine. J Infect Dis 180 (1999) 1171-1176
71. Black S., Shinefield H., Fireman B., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 (2000) 187-195
72. Givon-Lavi N., Frazer D., and Dagan R. Vaccination of day care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 22 (2003) 524-532
73. O'Brien K.L., Moulton L.H., Reid R., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 362 (2003) 355-361
74. Black S.B., Shinefield H.R., Ling S., et al. Effectiveness of heptavalent conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 (2002) 810-815
75. Dagan R., Sikuler-Cohen M., Zamir O., et al. Effect of conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day care center attendees. Pediatr Infect Dis J 20 (2001) 951-958
76. Fireman B., Black S.B., Shinefield H.R., et al. Impact of the pneumococcal vaccine on otitis media. Pediatr Infect Dis J 22 (2003) 10-16 [Erratum in: Pediatr Infect Dis J 2003;22:163.]
77. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against otitis media. N Engl J Med 344 (2001) 403-409
78. Kilpi T., Ahman H., Jokinen J., et al. Protective efficacy of a second pneumococcal conjugate vaccine against acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 166 children. Clin Infect Dis 37 (2003) 1155-1164
79. Toltzis P., and Jacobs M.R. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use. Infect Dis Clin North Am 19 (2005) 629-645
80. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54 (2005) 893-897
81. Stoll M.L., and Rubin L.G. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med 158 (2004) 671-675
82. Schutze G.E., Tucker N.C., and Maso Jr. E.O. Impact of the conjugate pneumococcal vaccine in Arkansas. Pediatr Infect Dis J 23 (2004) 1125-1129
83. Haddy R.I., Perry K., Chacko C.E., et al. Comparison of incidence of invasive Streptococcus pneumoniae among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J 24 (2005) 320-323
84. Hsu K., Pelton S., Karumuri S., et al. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 24 (2005) 17-23
85. Poehling K.A., Lafleur B.J., Szilagyi P.G., et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114 (2004) 755-761
86. Block S.L., Hedrick J., Harrison C., et al. Community wide vaccination with the heptavalent pneumococcal vaccine significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 23 (2004) 829-833
87. Lin P.L., Michaels M.G., Ortenzo M., et al. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center two years after licensure of the pneumococcal conjugate vaccine. Pediatrics 111 (2003) 896-899
88. Mahon B.E., Hsu K., Karumuri S., et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine 24 (2006) 2514-2520
89. Lexau C.A., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 (2005) 2043-2051
90. Feikin D.R., Klugman K.P., Facklam R.R., et al. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis 41 (2005) 481-487
91. Flannery B., Schrag S., and Bennett N.M. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infection. JAMA 291 (2004) 2253-2255
92. Talbot T.R., Poehling K.A., Hartent T.V., et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J 23 (2004) 726-731
93. Hennessy T.W., Singleton R.J., Bulkow L.R., et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska natives. Progress toward elimination of a health disparity. Vaccine 23 (2005) 5464-5473
94. Black S., Shinefield H., Baxter R., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23 (2004) 485-489
95. Kaplan S.L., Mason E.O., Wald E.R., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113 (2004) 443-449
96. Whitney C.G. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 24 (2005) 729-730
97. Byrington C.L., Samore M.H., Stoddard G.J., et al. Temporal trends of invasive disease due to streptococcus pneumoniae among children in the intermountain West: emergence of nonvaccine serogroups. Clin Infect Dis 41 (2005) 21-29
98. Long S.S. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 41 (2005) 30-34
99. Posfay-Barbe K.M., and Wald E.R. Pneumococcal vaccines: do they prevent infection and how?. Curr Opin Infect Dis 17 (2004) 177-184
100. McEllistrem M.C., Adams J., Mason E.O., et al. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 188 (2003) 1679-1684
101. Steele R.W., and Garrison N. Fever with bacteremia. A disappearing classic. Consultant for Pediatricians 4 (2005) 19-25
102. Green S.M., and Rothrock S.G. Evaluation styles for well-appearing febrile children: are you a "risk-minimizer" or a "test-minimizer"?. Ann Emerg Med 33 (1999) 211-214
103. Shah S.S., Shofer F.S., Seidel J.S., et al. Significance of extreme leukocytosis in the evaluation of febrile children. Pediatr Infec Dis J 24 (2005) 627-630
104. Dashefsky B., Teele D.W., and Klein J.O. Unsuspected meningococcemia. J Pediatr 102 (1983) 69-72
105. Kuppermann N., Malley R., Inkelis S.H., et al. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics 103 2 (1999) e20. http://pediatrics.aappublications.org/cgi/content/full/103/2/e20 Accessed May 26, 2006
106. Van Rossum A.M.C., Wulkan R.W., and Oudesluys-Murphy A.M. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 4 (2004) 620-630
107. Aronson M.D., and Bor H. Blood cultures. Ann Intern Med 106 (1987) 246-253
108. Bullock B. Fever without focus in the older infant. In: Moyer V.A., and Elliot E. (Eds). Evidence-based pediatrics and child health (2004), BMJ Books, London (England)
109. Kramer M.S., Lane D.A., and Mills E.L. Should blood cultures be obtained in the evaluation of young febrile children without evident focus of bacterial infection? A decision analysis of diagnostic management strategies. Pediatrics 84 (1989) 18-27
110. Kramer M. The young febrile child: Evidence-based diagnostic and therapeutic strategies. Emerg Med Pract 2 (2000) 1-24
111. Hoberman A., Chao H.P., Keller D.M., et al. Prevalence of urinary tract infection in febrile infants. J Pediatr 123 (1993) 17-23
112. Shaw K.N., and Gorelick M.H. Urinary tract infection in the pediatric patient. Pediatr Clin North Am 46 (1999) 1111-1124
113. Shaw K.N., Gorelick M.H., McGowan K.L., et al. Prevalence of urinary tract infection in febrile young children in the emergency department. Pediatrics 102 2 (1998) e16. http://www.pediatrics.org/cig/content/full/102/2/el6 Accessed May 26, 2006
114. Zorc J.J., Kiddoo D.A., and Shaw K.N. Diagnosis and management of pediatric urinary tract infection. Clin Microbiol Rev 18 (2005) 417-422
115. American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Urinary Tract Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. Pediatrics 103 (1999) 843-852
116. Ginsburg C.M., and McCracken G.H. Urinary tract infection in young infants. Pediatrics 69 (1982) 409-412
117. Schroeder A.R., Newman T.B., Wasserman R.C., et al. Choice of urine collection methods for the diagnosis of urinary tract infection in young febrile infants. Arch Pediatr Adolesc Med 159 (2005) 915-922
118. Hellerstein S. Recurrent urinary tract infections in children. Pediatr Infect Dis 1 (1982) 271-281
119. Whiting P., Westwood M., Watt I., et al. Rapid tests and urine sampling techniques for the diagnosis of urinary tract infection in children under five years. A systematic review. BMC Pediatr 5 4 (2005) 1-13
120. Huicho L., Campos Sanchez M., and Alamo C. Meta-analysis of urine screening tests for determining the risk of urinary tract infection in children. Pediatr Infect Dis J 21 (2002) 1-11
121. Hoberman A., Wald E.R., Penchansky L., et al. Enhanced urinalysis as a screening test for urinary tract infection. Pediatrics 91 (1993) 1196-1199
122. Bachur R., Perry H., and Harper M.B. Occult pneumonias: empiric chest radiographs in febrile children with leukocytosis. Ann Emerg Med 33 (1999) 166-173
123. Greenes D.S., and Harper M.B. Low risk of bacteremia in febrile children with recognizable viral syndromes. Pediatr Infect Dis J 18 (1999) 258-261
124. Vega R. Rapid viral testing in the evaluation of the febrile infant and child. Curr Opin Pediatr 17 (2005) 363-367
125. Finkelstein J.A., Schwartz J.S., Torrey S., et al. Common clinical features as predictors of bacterial diarrhea in infants. Am J Emerg Med 7 (1989) 469-473
126. DeWitt T.G., Humphrey K.F., and McCarthy P. Clinical predictors of acute bacterial diarrhea in young children. Pediatrics 76 (1985) 551-556
127. ACEP Clinical Policies Committee. Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med 42 (2003) 530-545
128. Lee G.M., Fleisher G.R., and Harper M.B. Management of febrile children in the age of pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics 108 (2001) 835-844
129. Yamamoto L.G. Revising the decision analysis for febrile children at risk for occult bacteremia in a future of widespread pneumococcal immunization. Clin Pediatr 40 (2001) 583-594
130. Klein J. Management of the febrile child without a focus of infection in the era of universal pneumococcal immunization. Pediatr Infect Dis J 21 (2002) 584-588
131. Kyaw M., Lyfield R., Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354 (2006) 1455-1463